MARKET

BMY

BMY

Bristol-Myers
NYSE

Real-time Quotes | Nasdaq Last Sale

66.92
-0.50
-0.74%
Closed 19:49 06/16 EDT
OPEN
67.42
PREV CLOSE
67.42
HIGH
67.86
LOW
66.84
VOLUME
10.80M
TURNOVER
--
52 WEEK HIGH
67.96
52 WEEK LOW
54.73
MARKET CAP
149.42B
P/E (TTM)
-24.0693
1D
5D
1M
3M
1Y
5Y
Orbimed Advisors Llc Buys Edgewise Therapeutics Inc, Silverback Therapeutics Inc, Gracell ...
GuruFocus News · 7h ago
Myovant and Partner Get Key Drug Approval
GuruFocus News · 15h ago
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc.
Benzinga · 16h ago
Is BMY Stock A Buy As Shares Surge On Promising Cancer Treatment Data?
Is BMY stock a buy after Bristol Myers Squibb said a cancer drug called Breyanzi outperformed the standard treatment in patients with a form of lymphoma?
Investor's Business Daily · 16h ago
Bristol Myers Squibb Co. stock outperforms market on strong trading day
marketwatch.com · 1d ago
Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers
Zacks.com · 1d ago
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.
Benzinga · 2d ago
Is Bristol Myers Squibb Company (BMY) Going to Burn These Hedge Funds?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money invest...
Insider Monkey · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BMY. Analyze the recent business situations of Bristol-Myers through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 20 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BMY stock price target is 75.37 with a high estimate of 90.00 and a low estimate of 62.00.
EPS
Institutional Holdings
Institutions: 2.90K
Institutional Holdings: 1.71B
% Owned: 76.70%
Shares Outstanding: 2.23B
TypeInstitutionsShares
Increased
967
66.26M
New
138
6.15M
Decreased
915
94.46M
Sold Out
118
8.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.39%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Chairman/Chief Executive Officer/Director
Giovanni Caforio
Chief Financial Officer/Executive Vice President
David Elkins
Chief Human Resource Officer/Senior Vice President
Ann Judge
Chief Human Resource Officer/Senior Vice President
Ann Powell
Executive Vice President/General Counsel
Sandra Leung
Executive Vice President
Christopher Boerner
Executive Vice President
Samit Hirawat
Executive Vice President
Elizabeth Mily
Executive Vice President
Louis Schmukler
Executive Vice President
Rupert Vessey
Senior Vice President/Chief Information Officer
Paul von Autenried
Senior Vice President/Chief Compliance Officer
Adam Dubow
Senior Vice President/Controller
Karen Santiago
Senior Vice President
Joseph Eid
Lead Director/Independent Director
Theodore Samuels
Director
Manuel Medina
Independent Director
Peter Arduini
Independent Director
Michael Bonney
Vice President/Director of Investor Relations/IR Contact Officer
Tim Power
Independent Director
Julia Haller
Lead Director/Independent Director
vicki Sato
Independent Director
Paula Price
Independent Director
Derica Rice
Independent Director
Gerald Storch
Independent Director
Karen Vousden
Independent Director
Phyllis Yale
Declaration Date
Dividend Per Share
Ex-Div Date
03/01/2021
Dividend USD 0.49
03/31/2021
12/10/2020
Dividend USD 0.49
12/31/2020
09/10/2020
Dividend USD 0.45
10/01/2020
06/11/2020
Dividend USD 0.45
07/02/2020
03/02/2020
Dividend USD 0.45
04/02/2020
12/05/2019
Dividend USD 0.45
01/02/2020
09/11/2019
Dividend USD 0.41
10/03/2019
06/13/2019
Dividend USD 0.41
07/03/2019
03/07/2019
Dividend USD 0.41
04/04/2019
12/06/2018
Dividend USD 0.41
01/03/2019
09/12/2018
Dividend USD 0.4
10/04/2018
06/14/2018
Dividend USD 0.4
07/05/2018
03/01/2018
Dividend USD 0.4
04/05/2018
12/07/2017
Dividend USD 0.4
01/04/2018
09/13/2017
Dividend USD 0.39
10/05/2017
06/14/2017
Dividend USD 0.39
07/05/2017
03/03/2017
Dividend USD 0.39
04/05/2017
12/09/2016
Dividend USD 0.39
01/04/2017
08/04/2016
Dividend USD 0.38
10/05/2016
06/13/2016
Dividend USD 0.38
06/29/2016
About BMY
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. Its products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. Its subsidiaries are Celgene Corp and MyoKardia, Inc.

Webull offers kinds of Bristol-Myers Squibb Co stock information, including NYSE:BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.